KYTHERA BIOPHARMACEUTICALS INC 4
4 · KYTHERA BIOPHARMACEUTICALS INC · Filed Oct 2, 2015
Insider Transaction Report
Form 4
TURNER JOSEPH L
Director
Transactions
- Disposition to Issuer
Common Stock
2015-10-01−1,872→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−5,672→ 0 totalExercise: $8.22Exp: 2022-02-01→ Common Stock (5,672 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−18,908→ 0 totalExercise: $1.35Exp: 2018-01-23→ Common Stock (18,908 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−5,672→ 0 totalExercise: $6.58Exp: 2021-03-15→ Common Stock (5,672 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−6,618→ 0 totalExercise: $21.65Exp: 2023-06-04→ Common Stock (6,618 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−8,400→ 0 totalExercise: $33.26Exp: 2024-06-05→ Common Stock (8,400 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−5,672→ 0 totalExercise: $16.00Exp: 2022-10-10→ Common Stock (5,672 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-10-01−11,591→ 0 totalExercise: $53.26Exp: 2025-06-02→ Common Stock (11,591 underlying)
Footnotes (2)
- [F1]Disposed of pursuant to the Amended and Restated Agreement and Plan of Merger dated as of August 4, 2015 (the "Merger Agreement"), by and among Allergan plc (formerly known as Actavis plc) ("Allergan"), Keto Merger Sub, Inc. (a wholly owned subsidiary of Allergan) and Issuer, whereby each share of Issuer common stock was canceled in exchange for $75.00 in cash, without interest.
- [F2]Pursuant to the Merger Agreement, each option to purchase common stock was canceled and paid in cash assuming a stock price of $75.00.